CYP19A1 Gene: Aromatase Enzyme, Estrogen Production, and Hormone Balance

Most people think of testosterone as a male hormone and estrogen as a female hormone. The reality is more interesting: estrogen is made from testosterone, in both sexes, by a single enzyme called aromatase. The gene that encodes aromatase — CYP19A1 — varies between individuals in ways that shift the androgen-to-estrogen balance across a lifetime.

Gnosis·Feb 28, 2026·8 min read

Key SNPs

CYP19A1 rs700519

Promoter region variant — affects transcription rate

C alleleHigher aromatase activity

CYP19A1 rs10046

3' UTR variant — affects mRNA stability

C alleleAssociated with higher circulating estradiol

How Aromatase Works

Aromatase is a cytochrome P450 enzyme encoded by CYP19A1. It catalyzes the conversion of androgens — primarily testosterone and androstenedione — into estrogens (estradiol and estrone). This conversion happens in multiple tissues: the gonads, adipose tissue, brain, bone, liver, and skin.

The rate of aromatization varies by tissue type, age, body composition, and — critically — genetics. Variants in CYP19A1 that increase aromatase expression or activity result in higher estrogen-to-androgen ratios. Those that reduce activity tip the balance the other direction.

Implications for Women

In premenopausal women, ovarian aromatase dominates estrogen production and CYP19A1 genotype has a relatively modest effect on overall estrogen levels. After menopause, ovarian production stops and peripheral aromatase (primarily in adipose tissue) becomes the main estrogen source. At this point, CYP19A1 genotype matters significantly more.

High-activity CYP19A1 variants are associated with higher postmenopausal estradiol levels, which has a complex risk profile: stronger bone protection and lower fracture risk, but higher risk of estrogen-receptor-positive breast cancer. This is why postmenopausal breast cancer risk models increasingly incorporate CYP19A1 genotype. Aromatase inhibitors (anastrozole, letrozole) — standard adjuvant therapy for ER+ breast cancer — work specifically by blocking this enzyme, and their efficacy is partly predicted by CYP19A1 variants.

Implications for Men

Men produce estrogen almost entirely through peripheral aromatization. Normal levels of estradiol are essential in men — for bone density, libido, mood stability, and cardiovascular function. But when aromatase activity runs high, more testosterone converts to estradiol, potentially leaving free testosterone lower than expected and raising estradiol above optimal range.

This is particularly relevant for men with higher body fat (adipose tissue is the primary peripheral aromatase site), men on testosterone replacement therapy, and men with symptoms of estrogen excess (water retention, gynecomastia, mood lability) despite normal testosterone levels. CYP19A1 variants explain why some men aromatize more aggressively than others on the same testosterone dose.

Optimizing Aromatase Activity by Genotype

Test estradiol and total/free testosterone together

A hormone panel that includes estradiol (not just testosterone) gives you the actual androgen-to-estrogen ratio. This is the starting point before any intervention. Target estradiol in men: 20–30 pg/mL. Women: varies by menstrual phase and menopausal status.

High-activity variants + excess adipose tissue: a compounding problem

Aromatase is highly expressed in fat tissue. Losing body fat reduces aromatization independent of genotype — and the combination of low-activity body weight with high-activity CYP19A1 can be addressed through both routes simultaneously.

Natural aromatase modulators

Zinc inhibits aromatase modestly and is worth supplementing if estradiol is elevated (25–50 mg zinc gluconate daily). Diindolylmethane (DIM) from cruciferous vegetables shifts estrogen metabolism toward less active metabolites. Chrysin has aromatase-inhibiting properties in vitro but poor bioavailability orally.

Alcohol significantly increases aromatase activity

Alcohol induces CYP19A1 expression acutely and chronically. Men with high-activity variants who drink regularly may see substantial estradiol elevation — far more than genetics alone would predict.

For TRT users: genotype guides AI use

Men on testosterone replacement with high-activity CYP19A1 variants typically need aromatase inhibitor support. This should be lab-guided, not automatic — but the genotype is a useful predictor of who will need management.

Check Your Hormone Genes

Upload your 23andMe or AncestryDNA file to see CYP19A1, AR, ESR1, and other hormone metabolism variants — analyzed privately in your browser.

Analyze Your Genome

Your data never leaves your device.

Research References

Simpson ER et al. Aromatase — a brief overview. Annu Rev Physiol. 2002;64:93–127.
Bulun SE et al. Aromatase in aging women. Semin Reprod Med. 2012;30(6):415–427.
Haiman CA et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007;67(5):1893–1897.